Halozyme Therapeutics (HALO) Revenue & Revenue Breakdown
Halozyme Therapeutics Revenue Highlights
Latest Revenue (Y)
$829.25M
Latest Revenue (Q)
$231.35M
Main Segment (Y)
Royalty
Main Geography (Y)
SWITZERLAND
Halozyme Therapeutics Revenue by Period
Halozyme Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $829.25M | 25.62% |
| 2022-12-31 | $660.12M | 48.91% |
| 2021-12-31 | $443.31M | 65.67% |
| 2020-12-31 | $267.59M | 36.53% |
| 2019-12-31 | $195.99M | 29.06% |
| 2018-12-31 | $151.86M | -52.04% |
| 2017-12-31 | $316.61M | 115.84% |
| 2016-12-31 | $146.69M | 8.61% |
| 2015-12-31 | $135.06M | 79.28% |
| 2014-12-31 | $75.33M | 37.47% |
| 2013-12-31 | $54.80M | 29.47% |
| 2012-12-31 | $42.33M | -24.54% |
| 2011-12-31 | $56.09M | 311.67% |
| 2010-12-31 | $13.62M | -0.35% |
| 2009-12-31 | $13.67M | 55.99% |
| 2008-12-31 | $8.76M | 130.66% |
| 2007-12-31 | $3.80M | 287.02% |
| 2006-12-31 | $981.75K | 671.76% |
| 2005-12-31 | $127.21K | 100.00% |
| 2004-12-31 | - | -100.00% |
| 2003-12-31 | $25.70K | -70.71% |
| 2002-12-31 | $87.77K | 255.56% |
| 2001-12-31 | $24.68K | - |
Halozyme Therapeutics generated $829.25M in revenue during NA 2023, up 25.62% compared to the previous quarter, and up 546.06% compared to the same period a year ago.
Halozyme Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $231.35M | 18.11% |
| 2024-03-31 | $195.88M | -14.85% |
| 2023-12-31 | $230.04M | 6.48% |
| 2023-09-30 | $216.03M | -2.26% |
| 2023-06-30 | $221.04M | 36.32% |
| 2023-03-31 | $162.14M | -10.66% |
| 2022-12-31 | $181.50M | -13.15% |
| 2022-09-30 | $208.98M | 37.15% |
| 2022-06-30 | $152.37M | 29.92% |
| 2022-03-31 | $117.28M | 14.98% |
| 2021-12-31 | $102.00M | -11.94% |
| 2021-09-30 | $115.83M | -15.11% |
| 2021-06-30 | $136.46M | 53.28% |
| 2021-03-31 | $89.02M | -26.85% |
| 2020-12-31 | $121.70M | 86.33% |
| 2020-09-30 | $65.32M | 18.28% |
| 2020-06-30 | $55.22M | 117.80% |
| 2020-03-31 | $25.35M | -52.76% |
| 2019-12-31 | $53.66M | 16.08% |
| 2019-09-30 | $46.23M | 18.09% |
| 2019-06-30 | $39.15M | -31.26% |
| 2019-03-31 | $56.95M | -5.45% |
| 2018-12-31 | $60.23M | 135.69% |
| 2018-09-30 | $25.56M | -27.40% |
| 2018-06-30 | $35.20M | 14.03% |
| 2018-03-31 | $30.87M | -83.71% |
| 2017-12-31 | $189.56M | 197.44% |
| 2017-09-30 | $63.73M | 88.83% |
| 2017-06-30 | $33.75M | 14.14% |
| 2017-03-31 | $29.57M | -24.19% |
| 2016-12-31 | $39.00M | 22.45% |
| 2016-09-30 | $31.85M | -4.45% |
| 2016-06-30 | $33.34M | -21.56% |
| 2016-03-31 | $42.50M | -18.63% |
| 2015-12-31 | $52.23M | 151.33% |
| 2015-09-30 | $20.78M | -52.10% |
| 2015-06-30 | $43.38M | 132.42% |
| 2015-03-31 | $18.67M | -38.55% |
| 2014-12-31 | $30.38M | 107.98% |
| 2014-09-30 | $14.61M | -20.55% |
| 2014-06-30 | $18.39M | 53.64% |
| 2014-03-31 | $11.97M | -4.26% |
| 2013-12-31 | $12.50M | -21.95% |
| 2013-09-30 | $16.01M | 10.79% |
| 2013-06-30 | $14.45M | 22.14% |
| 2013-03-31 | $11.83M | -45.70% |
| 2012-12-31 | $21.79M | 308.55% |
| 2012-09-30 | $5.33M | -31.23% |
| 2012-06-30 | $7.76M | 4.26% |
| 2012-03-31 | $7.44M | 208.57% |
| 2011-12-31 | $2.41M | -89.49% |
| 2011-09-30 | $22.94M | -1.06% |
| 2011-06-30 | $23.19M | 207.39% |
| 2011-03-31 | $7.54M | 111.16% |
| 2010-12-31 | $3.57M | 5.18% |
| 2010-09-30 | $3.40M | 5.70% |
| 2010-06-30 | $3.21M | -6.64% |
| 2010-03-31 | $3.44M | -46.59% |
| 2009-12-31 | $6.44M | 112.75% |
| 2009-09-30 | $3.03M | 112.38% |
| 2009-06-30 | $1.43M | -48.56% |
| 2009-03-31 | $2.77M | -9.46% |
| 2008-12-31 | $3.06M | 24.37% |
| 2008-09-30 | $2.46M | 71.68% |
| 2008-06-30 | $1.43M | -20.56% |
| 2008-03-31 | $1.81M | 34.95% |
| 2007-12-31 | $1.34M | - |
Halozyme Therapeutics generated $231.35M in revenue during Q2 2024, up 18.11% compared to the previous quarter, and up 142.68% compared to the same period a year ago.
Halozyme Therapeutics Revenue Breakdown
Halozyme Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $300.85M | $191.03M | $104.22M | $55.99M | $66.05M |
| Upfront fees | $2.00M | $30.00M | $42.00M | $37.26M | $53.00M |
| Sales-based milestone | - | $10.00M | $50.00M | $15.00M | - |
| Royalty | $447.87M | $360.48M | $203.90M | $88.60M | $69.90M |
| Research and Development Services | $9.53M | $9.61M | $1.19M | $1.25M | $1.54M |
| Collaborative Agreements | $80.53M | $108.61M | $135.19M | $123.01M | $60.05M |
| Bulk rHuPH20 | $115.44M | - | - | - | - |
| bulk rHuPH20 | - | $82.08M | $80.96M | $38.24M | $48.28M |
| Development Fees | - | $59.00M | $42.00M | $69.50M | $5.50M |
| Hylenex Recombinant | - | - | $23.26M | $17.03M | $17.00M |
| ENHANZE drug product | - | - | - | $719.00K | $768.00K |
Halozyme Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Royalty (46.84%), Product (31.46%), Bulk rHuPH20 (12.07%), Collaborative Agreements (8.42%), Research and Development Services (1.00%), and Upfront fees (0.21%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $72.70M | $79.60M | $86.57M | $73.89M | $60.79M | $61.16M | $61.43M | $46.30M | $22.14M | $25.05M | $30.36M | $21.77M | $32.45M | $9.05M | $6.34M | $8.15M | $22.69M | $29.20M | $5.76M | $8.39M |
| bulk rHuPH20 | $10.51M | $37.00M | $27.13M | $22.07M | $21.32M | $19.26M | $25.06M | $16.45M | $18.86M | $24.06M | $16.77M | $26.71M | $3.85M | $3.91M | $3.77M | $17.14M | $24.59M | $1.47M | $5.08M | - |
| Royalty | $120.59M | $122.05M | $114.43M | $111.74M | $99.64M | $105.98M | $99.55M | $85.34M | $69.61M | $58.56M | $45.78M | $36.92M | $32.00M | $23.93M | $15.85M | $16.82M | $17.23M | $16.61M | $18.11M | $17.95M |
| Collaborative Agreements | $16.70M | $28.39M | $15.03M | $35.41M | $1.71M | $14.35M | $48.00M | $20.73M | $25.53M | $32.22M | $60.32M | $30.33M | $57.25M | $32.34M | $33.04M | $385.00K | $13.74M | $416.00K | $15.28M | $30.61M |
| Upfront fees | - | - | - | - | - | - | - | $5.00M | $25.00M | $2.00M | $40.00M | $30.00M | - | $7.26M | - | $13.00M | - | $10.00M | $30.00M | - |
| Development Fees | - | - | - | - | - | - | $44.00M | $15.00M | - | - | - | $30.00M | $12.00M | $32.00M | $25.50M | - | $500.00K | - | $5.00M | - |
| Sales-based milestone | - | - | - | - | - | - | - | - | $30.00M | $20.00M | - | - | - | - | - | - | - | - | - | - |
| Research and Development Services | - | - | - | - | - | - | - | - | $534.00K | $220.00K | $317.00K | $333.00K | $251.00K | $337.00K | $274.00K | $385.00K | $242.00K | $416.00K | $281.00K | $606.00K |
| Hylenex Recombinant | - | - | - | - | - | - | - | - | $5.69M | $6.18M | $6.27M | $5.00M | $5.46M | $4.94M | $2.29M | $4.33M | $5.45M | $4.27M | $4.10M | $3.17M |
| ENHANZE drug product | - | - | - | - | - | - | - | - | - | - | $24.00K | - | $281.00K | $254.00K | $138.00K | $46.00K | $99.00K | $344.00K | $188.00K | $137.00K |
| License Fees And Event-Based | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.90M | $40.80M | - | - | - | - | - |
Halozyme Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Royalty (54.69%), Product (32.97%), Collaborative Agreements (7.57%), and bulk rHuPH20 (4.77%).
Halozyme Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 18 |
|---|---|
| SWITZERLAND | $109.89M |
| UNITED STATES | $40.48M |
Halozyme Therapeutics's latest annual revenue breakdown by geography, as of Dec 18: SWITZERLAND (73.08%), and UNITED STATES (26.92%).
Halozyme Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BGNE | BeiGene | $2.46B | $929.17M |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| EXEL | Exelixis | $1.83B | $637.18M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| INSM | Insmed | $305.21M | $90.34M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| ALEC | Alector | $97.06M | $15.89M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| INBX | Inhibrx | $1.80M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| DICE | DICE Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
HALO Revenue FAQ
What is Halozyme Therapeutics’s yearly revenue?
Halozyme Therapeutics's yearly revenue for 2023 was $829.25M, representing an increase of 25.62% compared to 2022. The company's yearly revenue for 2022 was $660.12M, representing an increase of 48.91% compared to 2021. HALO's yearly revenue for 2021 was $443.31M, representing an increase of 65.67% compared to 2020.
What is Halozyme Therapeutics’s quarterly revenue?
Halozyme Therapeutics's quarterly revenue for Q2 2024 was $231.35M, a 18.11% increase from the previous quarter (Q1 2024), and a 4.67% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $195.88M, a -14.85% decrease from the previous quarter (Q4 2023), and a 20.81% increase year-over-year (Q1 2023). HALO's quarterly revenue for Q4 2023 was $230.04M, a 6.48% increase from the previous quarter (Q3 2023), and a 26.75% increase year-over-year (Q4 2022).
What is Halozyme Therapeutics’s revenue growth rate?
Halozyme Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 87.06%, and for the last 5 years (2019-2023) was 323.11%.
What are Halozyme Therapeutics’s revenue streams?
Halozyme Therapeutics's revenue streams in c 23 are Product, Upfront fees, Royalty, Research and Development Services, Collaborative Agreements, and Bulk rHuPH20. Product generated $300.85M in revenue, accounting 31.46% of the company's total revenue, up 57.49% year-over-year. Upfront fees generated $2M in revenue, accounting 0.21% of the company's total revenue, down -93.33% year-over-year. Royalty generated $447.86M in revenue, accounting 46.84% of the company's total revenue, up 24.24% year-over-year. Research and Development Services generated $9.53M in revenue, accounting 1.00% of the company's total revenue, down -0.80% year-over-year. Collaborative Agreements generated $80.53M in revenue, accounting 8.42% of the company's total revenue, down -25.85% year-over-year. Bulk rHuPH20 generated $115.44M in revenue, accounting 12.07% of the company's total revenue
What is Halozyme Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Halozyme Therapeutics was Royalty. This segment made a revenue of $447.86M, representing 46.84% of the company's total revenue.